Extended-release Amphetamine Tablet Demonstrates Efficacy for Adult ADHD

An extended-release amphetamine tablet demonstrated efficacy and an anticipated safety profile in adults with attention-deficit/hyperactivity disorder (ADHD), researchers reported in a poster presentation at Psych Congress 2021.

For the 5-week, double-blind study, adults with ADHD were randomized to the daily extended-release amphetamine medication or placebo. Participants started with a 5-mg dose, which was titrated up to 20 mg in 5-mg increments each week. After visit 3, participants remained at the 20-mg dose for 2 weeks. Clinicians performed safety and efficacy assessments, including the Permanent Product Measure of Performance (PERMP), weekly. At visit 5, a serial PERMP assessment was administered before the morning dose and then at 0.5, 1, 2, 4, 8, 10, 12, 13, and 14 hours after the medication was taken.

Misconceptions, Treatment of Adult ADHD

The average PERMP score across all postdose timepoints on visit 5 was significantly higher in the extended-release amphetamine tablet group (302.8) compared with the placebo group (279.6), researchers reported.

Decreased appetite, insomnia, and dry mouth were common adverse events. Most treatment-emergent adverse events were mild to moderate in severity. No serious adverse events were reported.

Reference

Everitt A, Childress AC, Cutler A, et al. Randomized, double-blind, placebo-controlled, fixed-dose, parallel group study to evaluate the efficacy and safety of the amphetamine extended-release tablet (AMPH ER TAB) in adults with ADHD. Poster presented at: Psych Congress; October 29-November 1, 2021; San Antonio, TX.